{"id":59765,"date":"2024-02-28T06:15:13","date_gmt":"2024-02-28T06:15:13","guid":{"rendered":"https:\/\/medsname.com\/ventab-xl\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"ventab-xl","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/ventab-xl\/","title":{"rendered":"Ventab XL"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Ventab XL?<\/h3>\n
\n

Ventab XL<\/strong> inneh\u00e5ller venlafaxine ER (37.5 \/ 75 \/ 150 mg ER)<\/strong> from a WHO-GMP certified manufacturer (Intas Pharmaceuticals) — an SNRI<\/strong> with broad evidence in depression and anxiety-spectrum disorders. Standard start: 75 mg once daily<\/strong> with food; titrate to 150–225 mg\/day for full SNRI activity (max 375 mg in MDD, 225 mg in GAD\/social anxiety\/panic). Onset: 2–4 weeks. Below 150 mg the drug behaves mostly as an SSRI; norepinephrine reuptake inhibition appears at higher doses. Important<\/strong>: dose-dependent blood-pressure rise<\/strong> (BP must be monitored at > 225 mg). Has a severe discontinuation syndrome<\/strong> — mandatory taper. More dangerous in overdose than SSRIs (cardiac toxicity, seizures).<\/p>\n<\/div>\n

\nVad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade kundrecensioner<\/a>\n<\/div>\n

\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n

Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n

V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n<\/div>\n

Viktigt \u2014 detta \u00e4r inte ett l\u00e4kemedel f\u00f6r situationell \u00e5ngest.<\/strong> Ventab XL is a serotonin-norepinephrine reuptake inhibitor (SNRI)<\/strong>, som ordineras och titreras \u00f6ver veckor f\u00f6r major depressive disorder (MDD), generalised anxiety disorder (GAD), social anxiety disorder, and panic disorder<\/strong>. Det \u00e4r inte<\/strong> r\u00e4tt l\u00e4kemedel f\u00f6r akut, prestationsrelaterad \u00e5ngest (flygresor, offentliga tal, prov) \u2014 f\u00f6r dessa anv\u00e4ndningsomr\u00e5den \u00e4r betablockerare (propranolol), bensodiazepiner eller hydroxyzin kliniskt l\u00e4mpliga. Om du inte har en diagnostiserad hum\u00f6r-, \u00e5ngest- eller psykiatrisk st\u00f6rning, b\u00f6r du inte b\u00f6rja med denna medicin.<\/div>\n
FDA:s svartl\u00e5devarning \u2013 sj\u00e4lvmordsrisk.<\/strong> Alla antidepressiva b\u00e4r p\u00e5 en svartl\u00e5devarning fr\u00e5n FDA f\u00f6r \u00f6kad risk av sj\u00e4lvmordstankar och beteende hos barn, ton\u00e5ringar och unga vuxna under 25, s\u00e4rskilt under de f\u00f6rsta veckorna av behandling eller efter dos\u00e4ndringar. Anh\u00f6riga och f\u00f6rskrivare b\u00f6r noggrant \u00f6vervaka f\u00f6r f\u00f6rs\u00e4mrat hum\u00f6r, agitation eller sj\u00e4lvmordstankar i denna \u00e5ldersgrupp.<\/div>\n

What Is Ventab XL?<\/h2>\n

Ventab XL is an oral extended-release tablet\/capsule of venlafaxine (37.5 \/ 75 \/ 150 mg ER)<\/strong> manufactured by Intas Pharmaceuticals under WHO-GMP certification. Venlafaxine (US brand Effexor XR<\/strong>) is the prototype serotonin-norepinephrine reuptake inhibitor (SNRI)<\/strong>. It blocks both the serotonin transporter (SERT) at lower doses and the norepinephrine transporter (NET) at higher doses, producing a dose-dependent shift from SSRI-like to SNRI-like pharmacology.<\/p>\n

It is a first-line option in NICE and APA guidelines for major depression and is one of the most-evidenced antidepressants for generalised anxiety disorder.<\/p>\n

Godk\u00e4nda indikationer<\/h2>\n
    \n
  • Major depressiv st\u00f6rning (MDD)<\/strong> — including treatment-resistant depression at higher doses<\/li>\n
  • Generaliserat \u00e5ngestsyndrom (GAD)<\/strong><\/li>\n
  • Social anxiety disorder (chronic \/ generalised)<\/strong><\/li>\n
  • Panikst\u00f6rning<\/strong> — with and without agoraphobia<\/li>\n
  • Off-label: diabetic neuropathy, chronic fatigue, fibromyalgia, vasomotor symptoms of menopause<\/li>\n<\/ul>\n

    Dosering<\/h2>\n\n\n\n\n\n\n\n
    Indikation<\/th>\nB\u00f6rja med<\/th>\nTypical effective range<\/th>\nMaximalt<\/th>\nAnteckningar<\/th>\n<\/tr>\n<\/thead>\n
    MDD<\/td>\n75 mg\/day with food<\/td>\n150–225 mg\/day<\/td>\n375 mg\/day<\/td>\nIncrease by 75 mg every 2 weeks<\/td>\n<\/tr>\n
    GAD, social anxiety, panic<\/td>\n37.5–75 mg\/day<\/td>\n75–225 mg\/day<\/td>\n225 mg\/day<\/td>\nSlower up-titration in panic to avoid early agitation<\/td>\n<\/tr>\n
    Elderly \/ hepatic \/ renal impairment<\/td>\n37.5 mg\/day<\/td>\nUp to 75–150 mg with caution<\/td>\n\u2014<\/td>\nReduce by 25–50% in moderate hepatic impairment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Mechanism by Dose<\/h2>\n

    Pharmacology shifts as dose climbs<\/h2>\n\n\n\n\n\n\n\n\n
    Daglig dos<\/th>\nPharmacology<\/th>\nClinical relevance<\/th>\n<\/tr>\n<\/thead>\n
    37.5–75 mg<\/td>\nPredominantly serotonergic (SSRI-like)<\/td>\nUseful as a starting \/ sub-therapeutic dose for tolerability<\/td>\n<\/tr>\n
    75–150 mg<\/td>\nMostly serotonergic with emerging noradrenergic activity<\/td>\nLower end of antidepressant efficacy range<\/td>\n<\/tr>\n
    150–225 mg<\/td>\nCombined SERT + NET inhibition (true SNRI)<\/td>\nStandard effective dose for most adults; full SNRI benefit<\/td>\n<\/tr>\n
    225–375 mg (MDD only)<\/td>\nStrong SERT + NET inhibition<\/td>\nUsed in treatment-resistant depression; BP and cardiac monitoring required<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Biverkningar<\/h2>\n

    Vanliga, ih\u00e5llande och s\u00e4llsynta biverkningar<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Frekvens<\/th>\nEffekt<\/th>\nAnteckningar \/ hantering<\/th>\n<\/tr>\n<\/thead>\n
    Vanliga<\/td>\nNausea (dose-dependent)<\/td>\nTake with food; usually subsides over 1–2 weeks<\/td>\n<\/tr>\n
    Vanliga<\/td>\nHuvudv\u00e4rk, yrsel<\/td>\nTransient; adequate hydration<\/td>\n<\/tr>\n
    Vanliga<\/td>\nS\u00f6mnl\u00f6shet eller s\u00f6mnighet<\/td>\nOften dose in the morning if activating<\/td>\n<\/tr>\n
    Vanliga<\/td>\nDry mouth, constipation, sweating<\/td>\nSweating may persist; can be marked<\/td>\n<\/tr>\n
    Vanliga<\/td>\nSexuell dysfunktion<\/td>\nSimilar prevalence to SSRIs<\/td>\n<\/tr>\n
    Mindre vanligt<\/td>\nIncreased blood pressure (dose-dependent)<\/td>\nCheck BP at baseline and periodically; significant rise above 225 mg\/day in 5–10% — may need dose reduction or switch<\/td>\n<\/tr>\n
    Mindre vanligt<\/td>\nIncreased pulse, palpitations<\/td>\nCaution in patients with cardiac disease<\/td>\n<\/tr>\n
    Mindre vanligt<\/td>\nWeight changes (modest)<\/td>\nLess weight gain than paroxetine or mirtazapine<\/td>\n<\/tr>\n
    S\u00e4llsynt<\/td>\nHyponatremi (SIADH)<\/td>\n\u00c4ldre vuxna l\u00f6per st\u00f6rst risk<\/td>\n<\/tr>\n
    S\u00e4llsynt<\/td>\nBleeding risk<\/td>\nCaution with NSAIDs, anticoagulants<\/td>\n<\/tr>\n
    S\u00e4llsynt<\/td>\nSerotoninsyndrom<\/td>\nSee interactions<\/td>\n<\/tr>\n
    S\u00e4llsynt<\/td>\nMydriasis \/ acute angle-closure glaucoma<\/td>\nCaution in narrow-angle glaucoma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Avbrottssyndrom<\/h2>\n

    Venlafaxine has a short half-life<\/strong> (parent ~5 h; active metabolite desvenlafaxine ~11 h). Discontinuation symptoms are severe and rapid<\/strong>, second only to paroxetine: brain zaps, dizziness, nausea, sweating, irritability, insomnia, vivid dreams, flu-like aches. Often appear within 24–48 hours of a missed dose.<\/p>\n

    Mandatory slow taper<\/strong>: reduce by 75 mg every 2–4 weeks; below 75 mg use the smallest available capsule and consider every-other-day or hyperbolic tapering. Never stop abruptly. Patients on long-term venlafaxine often spend months on tapering — this is normal.<\/p>\n

    L\u00e4kemedelsinteraktioner<\/h2>\n

    Absoluta kontraindikationer<\/strong>: MAOIs, linezolid, methylene blue. 14-day washout.<\/p>\n

    Serotonergic interactions<\/strong>: triptans, tramadol, pethidine, dextromethorphan, St John’s wort, lithium — serotonin syndrome risk.<\/p>\n

    CYP2D6 substrate<\/strong>: levels rise with strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine). Consider dose reduction.<\/p>\n

    Bleeding risk<\/strong>: NSAIDs, aspirin, warfarin, DOACs.<\/p>\n

    Cardiac and Overdose Considerations<\/h2>\n

    Venlafaxine is more dangerous in overdose than SSRIs<\/strong>: cardiac conduction abnormalities, QT prolongation, seizures, and serotonin syndrome have been reported. Provide only short supplies to patients at acute suicide risk. Pre-existing significant cardiac disease, recent MI, or uncontrolled hypertension are relative contraindications.<\/p>\n

    Vanliga fr\u00e5gor<\/h2>\n

    How long does Ventab XL take to work?<\/h3>\n

    Anxiety symptoms often improve in 2–3 weeks; mood response in MDD typically appears at 4–6 weeks. Patients on sub-therapeutic doses (< 150 mg) may need dose escalation before seeing full benefit.<\/p>\n

    Why does the dose matter so much for venlafaxine?<\/h3>\n

    Below 150 mg\/day, venlafaxine acts mostly like an SSRI — norepinephrine reuptake inhibition appears only at higher doses. Patients who don’t respond at 75 mg often respond once titrated to 150 mg or above.<\/p>\n

    Will Ventab XL raise my blood pressure?<\/h3>\n

    Possibly — venlafaxine causes dose-dependent BP increases. Below 150 mg the effect is small; above 225 mg, 5–10% of patients see clinically significant increases. BP should be monitored at baseline and after dose escalations.<\/p>\n

    Can I stop Ventab XL abruptly?<\/h3>\n

    No — venlafaxine has one of the worst discontinuation syndromes in the antidepressant class (brain zaps, dizziness, nausea, sweating). Mandatory taper, often over months for long-term users.<\/p>\n

    Is Ventab XL safe in pregnancy?<\/h3>\n

    Limited data — not the first-choice antidepressant in pregnancy. Sertraline is preferred. Late-third-trimester exposure carries a small risk of neonatal adaptation syndrome and persistent pulmonary hypertension of the newborn.<\/p>\n

    Does Ventab XL cause weight gain?<\/h3>\n

    Less than paroxetine or mirtazapine. Some patients see modest weight changes; others lose weight from initial GI side effects. Less metabolic burden than antipsychotics.<\/p>\n

    Can I drink alcohol on Ventab XL?<\/h3>\n

    Light, occasional alcohol is generally tolerated. Heavy alcohol use worsens depression \/ anxiety, increases sedation, and is implicated in disinhibited behaviour.<\/p>\n

    Vad h\u00e4nder om jag missar en dos?<\/h3>\n

    Take it as soon as you remember unless close to the next dose. Withdrawal symptoms can begin within 24–48 hours of a missed dose — do not skip multiple doses.<\/p>\n

    How is Ventab XL different from duloxetine or desvenlafaxine?<\/h3>\n

    All are SNRIs. Duloxetine has a different binding profile (more SNRI even at lower doses, hepatic concerns), is also approved for diabetic neuropathy and fibromyalgia. Desvenlafaxine is the active metabolite of venlafaxine — bypasses CYP2D6 metabolism, more predictable plasma levels.<\/p>\n

    How should Ventab XL be stored?<\/h3>\n

    Store at 15–30 °C in the original blister packaging, away from moisture and sunlight. Keep out of reach of children — venlafaxine overdose is medically significant.<\/p>\n

    Medicinsk ansvarsfriskrivning:<\/strong> Informationen p\u00e5 denna sida \u00e4r avsedd f\u00f6r vuxna som anv\u00e4nder receptbelagd psykiatrisk medicin och \u00e4r inte en ers\u00e4ttning f\u00f6r individuell medicinsk r\u00e5dgivning. Antidepressiva, antipsykotika och relaterade l\u00e4kemedel kan interagera med andra l\u00e4kemedel, alkohol och underliggande sjukdomar. Diskutera alla nya l\u00e4kemedel, dos\u00e4ndringar eller planerad avslutning med en kvalificerad l\u00e4kare. Om du upplever sj\u00e4lvmordstankar, mani, sv\u00e5r akatisi, tecken p\u00e5 serotoninergt syndrom (h\u00f6g feber, f\u00f6rvirring, muskelstelhet, snabb hj\u00e4rtfrekvens) eller neuroleptiskt malign syndrom, s\u00f6k akut v\u00e5rd omedelbart.<\/div>\n

    <\/p>\n

    Relaterade alternativ<\/h3>\n

    Andra produkter inom Kroniska tillst\u00e5nd<\/strong> som kunder \u00e4ven tittar p\u00e5:<\/p>\n